Abnova (Taiwan) Corporation (TPE:4133)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
24.00
-0.20 (-0.83%)
Jan 22, 2026, 1:03 PM CST
-18.09%
Market Cap1.47B
Revenue (ttm)355.40M
Net Income (ttm)1.80M
Shares Out60.55M
EPS (ttm)0.03
PE Ratio814.11
Forward PEn/a
Dividend0.90 (3.70%)
Ex-Dividend DateJun 16, 2025
Volume48,511
Average Volume75,788
Open24.30
Previous Close24.20
Day's Range24.00 - 24.35
52-Week Range21.70 - 35.10
Beta0.39
RSI68.77
Earnings DateFeb 26, 2026

About Abnova (Taiwan)

Abnova (Taiwan) Corporation manufactures and sells various recombinant proteins and antibodies. The company’s products portfolio includes SARS-CoV/CoV-2 DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems, and automations. It also offers MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies. In addition, the company provides integrated solutions and services, including gene synthesis an... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 4133
Full Company Profile

Financial Performance

In 2024, Abnova (Taiwan)'s revenue was 355.26 million, a decrease of -7.01% compared to the previous year's 382.05 million. Earnings were 61.61 million, an increase of 41.05%.

Financial Statements